---
title: "Remedium Lifecare Ltd (539561) — Share Price, Financials & Analysis"
symbol: "539561"
company: "Remedium Lifecare Ltd"
canonical: "https://tapetide.com/stocks/539561"
isin: "INE549S01036"
nse_symbol: "REMEDIUMFECARELTD"
bse_code: "539561"
sector: "Commercial Services"
industry: "Trading & Distributors"
market_cap_cr: 23.8
generated_at: "2026-09-13T18:21:46.052Z"
---

# Remedium Lifecare Ltd (539561)

Canonical page: https://tapetide.com/stocks/539561

## Company

- **NSE Symbol:** REMEDIUMFECARELTD
- **BSE Code:** 539561
- **ISIN:** INE549S01036
- **Sector:** Commercial Services
- **Industry:** Trading & Distributors
- **Macro Sector:** Services
- **Stock Type:** EQUITY
- **Listed Since:** 2018-05-25
- **CEO:** Mr. Adarsh Munjal
- **Employees:** 7
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** remlife.com

## About

Supha Pharmachem Ltd, formerly Remedium Lifecare, is a pharmaceutical supply-chain trader of APIs, advanced intermediates, KSMs/CRMs and other pharma chemicals for domestic and export markets. It operates through the Indian parent and Singapore subsidiary Remlife Global Pte Ltd and entered CIRP on March 17, 2026. [1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:33:58.052370Z.

- **Market Cap:** ₹23.8 Cr
- **Classification:** Microcap
- **P/E (reported):** 13.5
- **Book Value:** ₹1.04
- **Price to Book:** 0.26
- **Dividend Yield:** 0%
- **ROE:** 4.85%
- **ROCE:** 22.04%
- **Debt to Equity:** 25.93
- **Revenue (yearly):** ₹416.1 Cr
- **Net Income:** ₹2.1 Cr
- **EBITDA:** ₹9.7 Cr
- **52-Week High:** ₹1.8
- **52-Week Low:** ₹0.25
- **RSI (14):** 35.31

## Tapetide Score

- **Score:** 39 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Fair · Momentum: Falling
- **Percentile:** 12 (of 4473 scored stocks)
- **Confidence:** 85%
- **Data coverage:** 86%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 43.34 | 9.89% |
| momentum | 7.72 | 13.19% |
| ownership | 66.3 | 26.37% |
| quality | 14.3 | 24.18% |
| valuation | 51.74 | 26.37% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.22 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- Promoter holding is low: 1.13%
- Earnings include an other income of Rs.10.8 Cr.
- Company has high debtors of 695 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y |
| --- | --- | --- | --- |
| cash flow growth | — | -264.03% | -707.14% |
| ebitda margin growth | 96.3% | — | — |
| net income growth | 82.98% | — | — |
| revenue growth | -2.22% | — | — |
| roce | 98.69% | — | — |
| roe | 85.38% | — | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 | Jun 2025 | Sep 2025 |
| --- | --- | --- | --- |
| Sales | 264.32 | 113.37 | 111.06 |
| Expenses | 264.78 | 111.5 | 103.68 |
| Operating Profit | -0.46 | 1.87 | 7.38 |
| OPM % | -0.17 | 1.65 | 6.65 |
| Other Income | 0.66 | 3.48 | 3.25 |
| Interest | 1.59 | -0.36 | 0.19 |
| Depreciation | 0.01 | 0 | 0 |
| Profit before tax | -1.4 | 5.71 | 10.44 |
| Tax % | 45.71 | 18.56 | 17.34 |
| Net Profit | -2.05 | 4.65 | 8.62 |
| EPS in Rs | -0.02 | 0.05 | 0.1 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 |
| --- | --- |
| Sales | 405 |
| Expenses | 404 |
| Operating Profit | 1 |
| OPM % | 0.3 |
| Other Income | 11 |
| Interest | 8 |
| Depreciation | 0 |
| Profit before tax | 4 |
| Tax % | 51 |
| Net Profit | 2 |
| EPS in Rs | 0.02 |
| Dividend Payout % | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 | Sep 2025 |
| --- | --- | --- |
| Equity Capital | 40 | 88 |
| Reserves | 4 | 17 |
| Borrowings | 1141 | 1088 |
| Other Liabilities | 535 | 430 |
| Total Liabilities | 1720 | 1623 |
| Fixed Assets | 0 | 6 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 1720 | 1617 |
| Total Assets | 1720 | 1623 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 |
| --- | --- |
| Cash from Operating Activity | -1135 |
| Cash from Investing Activity | 0 |
| Cash from Financing Activity | 1136 |
| Net Cash Flow | 1 |
| Free Cash Flow | -1135 |
| CFO/OP | -90064 |

### Ratios

| Item | Mar 2025 |
| --- | --- |
| Debtor Days | 695 |
| Inventory Days | 247 |
| Days Payable | 459 |
| Cash Conversion Cycle | 483 |
| Working Capital Days | 38 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 1.11% | 1.11% | 1.11% | 1.11% | 1.11% | 1.11% | 1.11% | 1.11% | 1.11% | 1.13% | 1.13% | 1.13% |
| FIIs | 0% | 0% | 0% | 0.04% | 0.04% | 0% | 0% | 0% | 0% | 0% | 0% | 1.7% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 86.24% | 86% | 80.87% | 80.3% | 82.21% | 83.33% | 85.01% | 86.1% | 87.29% | 78.39% | 79.02% | 81.29% |
| Others | 12.65% | 12.89% | 18.02% | 18.54% | 16.64% | 15.56% | 13.87% | 12.79% | 11.6% | 20.48% | 19.85% | 15.88% |
| No. of Shareholders | 705 | 1730 | 3988 | 3859 | 15587 | 26464 | 67404 | 73637 | 110422 | 113543 | 114119 | 111269 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 4 / 3 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 0.28 | Sell |
| EMA (10) | 0.28 | Sell |
| SMA (20) | 0.29 | Sell |
| EMA (20) | 0.29 | Sell |
| SMA (50) | 0.31 | Sell |
| EMA (50) | 0.31 | Sell |
| SMA (100) | 0.33 | Sell |
| EMA (100) | 0.39 | Sell |
| SMA (200) | 0.64 | Sell |
| EMA (200) | 0.65 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 31.56 | Neutral |
| MACD (12,26,9) | -0.01 | Sell |
| Stochastic (14,3,3) | 16.67 | Buy |
| ADX (14) | 36.46 | Buy |
| Williams %R (14) | -100 | Buy |
| ATR (14) | 0.01 | High Volatility |
| ROC (12) | -13.33 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 50.75 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-06-30 | [Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Regarding The Order Passed By HonBle National Company Law Appellate Tribunal (NCLAT) Principal Bench New Delhi](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2099ab4f-810b-4aa8-9b93-7d096ea402be.pdf) |
| 2026-06-27 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ab0b1cc-30cd-426e-8eff-6596c1e4097e.pdf) |
| 2026-05-12 | [Intimation Of Change In Insolvency Professional - Appointment Of Resolution Professional (RP) In Place Of Interim Resolution Professional (IRP)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a027851-9b54-471c-be91-ed0c68dbd64a.pdf) |
| 2026-04-17 | [Post- Coc Update](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4afc2aad-f348-4972-8007-0dff222178f7.pdf) |
| 2026-04-10 | [Corporate Insolvency Resolution Process (CIRP)-List of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c4efe262-2968-401d-bb83-b51c79df3c86.pdf) |
| 2026-04-02 | [Postponement Of Board Meeting Under Regulation 30 Of SEBI (LODR) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25addfc7-6332-4e70-a732-52c894ef40d9.pdf) |
| 2026-03-25 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32b945c5-a3ba-4385-9da2-864ad0e95896.pdf) |
| 2026-03-21 | [Intimation Of Receipt Of Order From National Company Law Tribunal (NCLT)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21f76a1d-9d4a-4fa3-8aeb-45cf25255000.pdf) |
| 2026-03-20 | [Submission Of Form A - PUBLIC ANNOUNCEMENT](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2281c8d-be56-45f9-9ef0-33fffcc8bd69.pdf) |
| 2026-03-19 | [Announcement under Regulation 30 (LODR)-Appointment of Interim Resolution Professional (IRP)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79e91390-490a-4584-a337-39d7149ff4c3.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Mar - Board meeting rescheduled to March 30, 2026; consolidated results delayed due to Singapore subsidiary; trading window closed. | [Board Meeting Intimation for To Consider Un-Audited Financial Results/Statements (Standalone & Consolidated) Of The Company For The Third Quarter And Nine Months Ended December, 31, 2025 And Update On Trading Window 9 Mar - Board meeting rescheduled to March 30, 2026; consolidated results delayed due to Singapore subsidiary; trading window closed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/37fd6b67-0884-4599-a47d-2157ae01bb30.pdf) |
| 3 Feb - Unaudited Q3/9M FY26 results: Q3 revenue Rs3,007.69cr, Q3 net loss Rs243.97cr; 9M revenue Rs9,762.81cr, loss Rs333.19cr. | [Board Meeting Outcome for Integrated Filing (Financials) For The Quarter And Nine Months Ended 31.12.2025. 3 Feb - Unaudited Q3/9M FY26 results: Q3 revenue Rs3,007.69cr, Q3 net loss Rs243.97cr; 9M revenue Rs9,762.81cr, loss Rs333.19cr.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e90dbb7b-3c01-4287-b5a7-14edd4ce6e7a.pdf) |
| 3 Feb - Board meeting on 14 Feb 2026 to consider Q3 and 9M unaudited results for Dec 31, 2025; trading window closed. | [Board Meeting Intimation for Consider Un-Audited Financial Results/Statements (Standalone & Consolidated) Of The Company For The Third Quarter And Nine Months Ended December, 31, 2025 3 Feb - Board meeting on 14 Feb 2026 to consider Q3 and 9M unaudited results for Dec 31, 2025; trading window closed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/78f5d9f9-9c38-4e3d-a002-7c9409248e1b.pdf) |
| 29 Jan - Board meeting 3 Feb 2026 to approve unaudited results for quarter ended 31 Dec 2025; trading window Jan 1–Feb 5. | [Board Meeting Intimation for Consideration Of Unaudited Financial Results Of The Company For Quarter Ended 31St December 2025 29 Jan - Board meeting 3 Feb 2026 to approve unaudited results for quarter ended 31 Dec 2025; trading window Jan 1–Feb 5.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b1501a3e-a7dc-4920-8e32-9e8de390624a.pdf) |
| 27 Jan - Shri Amitava Mukherjee given additional charge as Director (Finance) NMDC Steel Ltd from 06.12.2025 to 05.03.2026. | [Entrusting Of Additional Charge Of The Post Of Director (Finance), NMDC Steel Ltd. To Shri Amitava Mukherjee, Chairman & Managing Director. 27 Jan - Shri Amitava Mukherjee given additional charge as Director (Finance) NMDC Steel Ltd from 06.12.2025 to 05.03.2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/55fc7199-3cd9-4d9c-a636-30c66b8c4262.pdf) |
| 25 Feb - Board meeting postponed to 9 Mar 2026; Q3/9M Dec 31, 2025 results delayed; trading window closed. | [Board Meeting Intimation for Rescheduled Of Board Meeting On 09.03.2026 25 Feb - Board meeting postponed to 9 Mar 2026; Q3/9M Dec 31, 2025 results delayed; trading window closed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a5795ceb-e04d-46de-9957-a9d0e790f9f3.pdf) |
| 21 Mar - NCLT admitted CIRP against Remedium Lifecare for Rs.7.47 crore debt; moratorium declared and IRP appointed (17-Mar-2026). | [Intimation Of Receipt Of Order From National Company Law Tribunal (NCLT) 21 Mar - NCLT admitted CIRP against Remedium Lifecare for Rs.7.47 crore debt; moratorium declared and IRP appointed (17-Mar-2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/21f76a1d-9d4a-4fa3-8aeb-45cf25255000.pdf) |
| 20 Mar - NCLT commenced CIRP on 17-03-2026; IRP appointed; claims due 31-03-2026. | [Submission Of Form A - PUBLIC ANNOUNCEMENT 20 Mar - NCLT commenced CIRP on 17-03-2026; IRP appointed; claims due 31-03-2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c2281c8d-be56-45f9-9ef0-33fffcc8bd69.pdf) |
| 20 Jan - Submission of Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31.12.2025 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 20 Jan - Submission of Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31.12.2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cda82f3f-6175-4f21-be48-a2e5a568d5e7.pdf) |
| 2 Apr - IRP reports suspended directors' non-cooperation; 30 Mar 2026 results meeting postponed under CIRP. | [Postponement Of Board Meeting Under Regulation 30 Of SEBI (LODR) Regulations, 2015 2 Apr - IRP reports suspended directors' non-cooperation; 30 Mar 2026 results meeting postponed under CIRP.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/25addfc7-6332-4e70-a732-52c894ef40d9.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2025-11-14 | [Results - Financial Results For Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c45fd72-734c-4e2f-bbf3-be766dc476ce.pdf) |
| 2025-08-04 | [Results For The Quarter Ended June 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7e14d671-7ae3-4dc0-b6a8-2b9d67b00f58.pdf) |
| 2025-05-30 | [The Audited Financial Results (Standalone And Consolidated) Of The Company For The Last Quarter And Year Ended March 31 2025 And Audited Annual Accounts Of The Company For The Quarter And Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5689402b-1142-4c3d-bbeb-55065697f4b8.pdf) |
| 2025-02-14 | [Results For The Quarter And Nine Months Ended December 31 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb94f995-b7f1-4ddc-a720-18bb44b057a6.pdf) |
| 2024-11-14 | [Results For The Quarter And Half Year Ended September 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b7dabb5-a26d-4528-9c17-7ece41e2d164.pdf) |
| 2024-08-14 | [Results For The Quarter Ended June 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b489ba4-5273-477b-8edb-9a63f2ee5fda.pdf) |
| 2024-05-27 | [Results For The Quarter And Year Ended 31.03.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c9175c04-1330-4c72-9e57-85417436e202.pdf) |
| 2024-02-14 | [Unaudited Financial Results For The Quarter And Nine Months Ending 31.12.2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7aefd842-653b-4c71-bedc-abd7788aaf72.pdf) |
| 2023-11-11 | [Unaudited Financial Results For The Quarter And Half Year Ending 30.09.2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fb3ec269-bbf0-4f50-9399-0512abf1199f.pdf) |
| 2023-08-12 | [Board Meeting Outcome for Meeting Held On Saturday, August 12, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dab221b5-9168-4811-8c48-fdce5de761a6.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a85eb11a-1a10-4810-ba2b-48e2e3c76393.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/53b57272-6733-4885-afae-37c7d4565f39.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f0065e8f-6c13-41c7-96b5-38d3df24e970.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6f26a59b-6b1f-4863-97bc-7bb3506c527a.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/44a71092-badf-4d0e-8823-34ba8b89ef29.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/da59e166-ec9e-406a-98be-700df9e26f9f.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/539561/74843539561.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/539561/70637539561.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/539561/66666539561.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/539561/5395610319.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:21:46.052Z.